Artal Group S.A. Neurocrine Biosciences Inc Call Options Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $16.8 Million - $20.3 Million	-200,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$69.31 - $91.53 $13.9 Million - $18.3 Million	200,000 New	200,000 $17.6 Million
Q2 2018 Aug 10, 2018	SELL	$75.3 - $105.99 $7.53 Million - $10.6 Million	-100,000 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$75.88 - $92.43 $7.59 Million - $9.24 Million	100,000 New	100,000 $8.29 Million

625

95.2M

661K

227K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.